|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Outcome of patients with radiation enteritis treated with home parenteral nutrition显示文摘 | James S Scolapio Andrzej Ukleja Jan U Burnes Darlene G Kelly | 2002 | The American Journal of Gastroenterology2002，，3： | 1 |
| 2 | Outcome of patients with radiation enteritis treated with home parenteral nutrition 显示文摘 | Scolapio JS Ukleja A Burnes JU | 2002 | Am J Gastroenterol2002，97，： | 1 |
| 3 | Decreasing aspiration risk with enteral feeding显示文摘 | Scolapio JS | 2007 | Gastrointest Endosc Clin N Am2007，17，4： | 1 |
| 4 | Current update of short-bowel syndrome显示文摘 | Scolapio JS | 2004 | Curr Opin Gastroenterol2004，20，2： | 1 |
| 5 | Effect of growth hormone,glutamine,and diet on adaptation in short-bowel syndrome:a randomized,controlled study显示文摘 | Scolapio JS Camilleri M Fleming CR | 1997 | Gastroenterology1997，113，4： | 1 |
| 6 | AGA technical review of short bowel syndrome and intestinal transplantation 显示文摘 | Buchman AL Scolapio J Fryer J | 2003 | Gastroenterology2003，124，4： | 1 |
| 7 | Audit of nutrition support for hematopoietic stem cell transplantation at a single institution显示文摘 | Scolapio JS Tarrosa VB Stoner GL | 2002 | Mayo Clin Proc2002，77，7： | 1 |
| 8 | Success with intestinal failure:from adaptation to transplantation显示文摘 | Scolapio JS Nguyen JH Steers J | 1999 | Dig Dis1999，17，2： | 1 |
| 9 | Contribution of ascites to impaired gastric function and nutritional intake in patients with cirrhosis and ascites显示文摘 | Aqel BA Scolapio JS Dickson RC | 2005 | Clin Gastroenterol Hepatol2005，3，11： | 1 |
| 10 | Out come of patients with radiationsenteritis treated with home parenteral nurtrition 显示文摘 | Scolapio JR Ukleja Aburnes JU | 2002 | Am J Gastroenterol2002，97，3： | 1 |
| 11 | Effect of growth hormone,glutamine,and diet on adaptation in short-bowel syndrome:a randomized,controlled study显示文摘 | Scolapio JS Camilleri M Fleming CR | 1997 | Gastroenterology1997，113，： | 1 |
| 12 | Survival of home parenteral nutrition-treated patients: 20 years of experience at the Mayo Clinic 显示文摘 | Scolapio JS Fleming CR Kelly DG | 1999 | Mayo Clin Proc1999，74，： | 1 |
| 13 | Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report显示文摘BACKGROUND A variety of immune-modulating drugs are becoming increasingly used for various cancers. Despite increasing indications and improved efficacy, they are often associated with a wide variety of immune mediated adverse events including colitis that may be refractory to conventional therapy. Although these drugs are being more commonly used by Hematologists and Oncologists, there are still many gastroenterologists who are not familiar with the incidence and natural history of gastrointestinal immune-mediated side effects, as well as the role of infliximab in the management of this condition.CASE SUMMARY We report a case of a 63-year-old male with a history of metastatic renal cell carcinoma who presented to our hospital with severe diarrhea. The patient had received his third combination infusion of the anti-CTLA-4 monoclonal antibody Ipilimumab and the immune checkpoint inhibitor Nivolumab and developed severe watery non-bloody diarrhea the same day. He presented to the hospital where he was found to be severely dehydrated and in acute renal failure. An extensive workup was negative for infectious etiologies and he was initiated on high dose intravenous steroids. However, he continued to worsen. A colonoscopy was performed and revealed no endoscopic evidence of inflammation. Random biopsies for histology were obtained which showed mild colitis, and were negative for Cytomegalovirus and Herpes Simplex Virus. He was diagnosed with severe steroid-refractory colitis induced by Ipilimumab and Nivolumab and was initiated on Infliximab. He responded promptly to it and his diarrhea resolved the next day with progressive resolution of his renal impairment. On follow up his gastrointestinal side symptoms did not recur.CONCLUSION Given the increasing use of immune therapy in a variety of cancers, it is important for gastroenterologists to be familiar with their gastrointestinal side effects and comfortable with their management, including prescribing infliximab. | Ammar B Nassri Valery Muenyi Ahmad AlKhasawneh Bruno De Souza Ribeiro James S Scolapio Miguel Malespin Silvio W de Melo Jr | 2019 | World Journal of Gastrointestinal Pharmacology and Therapeutics2019，10，1： | 1 |
| 14 | Tedaglutide for the treatment of short bowel syndrome 显示文摘 | Ferrone M Scolapio JS | 2006 | Ann Pharmacother2006，40，6： | 1 |
| 15 | Pancreatic enzyme pharmacotherapy 显示文摘 | FERRONE M RAIMONDO M SCOLAPIO JS | 2007 | Pharmacotherapy2007，27，6： | 1 |
| 16 | Effect of growth hormone,glutamine and diet on adaptation in short bowel syndrome.A randomized controlled study显示文摘 | Scolapio JS Camilleri MC Fleming CR | | 0，，： | 1 |
| 17 | A review of the trends in the use of enteral and parenteral nutrition support显示文摘 | Scolapio JS | 2004 | J Clin Gastroenterol2004，38，5： | 1 |
| 18 | Contribution of asci- tes to impaired gastric function and nutritional intake in patients with cirrhosis and aseites 显示文摘 | Aqel BA Scolapio JS Dickson RC | 2005 | Clin Gastroenterol Hepatol2005，3，11： | 1 |
| 19 | Effect of glutamine in short bowel syndrome显示文摘 | Scolapio JS MoGreery K Tennyson GS | | 0，，： | 1 |
| 20 | Enteral versus parenteral nutrition:the patient's preference显示文摘 | Scolapio JS Pieeo MF Tarrosa VB | 2002 | JPEN J Parenter Enteral Nutr2002，26，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员